TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24802657
Drug: Lobeglitazone 2
Normalized name: rosiglitazone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobeglitazone 2 mg
Study: 24802657
Drug: Lobeglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobeglitazone 4 mg
Study: 23158229
Drug: Maternal anthelminthic
Normalized name: pyrantel
DrugBank: Pyrantel (DB11156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal anthelminthic treatment during pregnancy
Study: 20926997
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of corticosteroid
Study: 18514620
Drug: Oral amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amino acid supplements alongside ACE inhibitor therapy
Study: 18514620
Drug: Placebo alongside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo alongside ACE inhibitor therapy
Study: 15928545
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment and group exercise
Study: 12074417
Drug: Volatile inhalation
Normalized name: Peppermint volatile oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volatile inhalation induction and maintenance (Group 1)
Study: 12074417
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia with propofol and a minimal dose sufentanil (Group 2)
Study: 12074417
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose midazolam-sufentanil (Group 3)
Study: 28298024
Drug: Subcutaneous IL-1
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous IL-1 receptor antagonist (IL-1Ra) 100 mg administered twice daily for up to 21 days postictus.
Study: 24517632
Drug: Low HDL-C
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low HDL-C group (<40 mg/dL)
Study: 20170522
Drug: LeptiCore formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: LeptiCore formula A (low dose)
Study: 20170522
Drug: LeptiCore formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: LeptiCore formula B (high dose)
Study: 15606439
Drug: Epinastine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinastine (10 mg for 14 kg to <24 kg; 20 mg for ≥24 kg)
Study: 15606439
Drug: Epinastine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinastine (20 mg)
Study: 11911720
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) for 1 year during PEPI-RCT
Study: 11911720
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) for 3 years during PEPI-RCT
Study: 18598891
Drug: No Hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Hormone Replacement Therapy (Control)
Study: 11911720
Drug: Continued Hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued Hormone Replacement Therapy (HRT) after PEPI-RCT
Study: 10102410
Drug: Pergolide (0.51
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (0.51 mg as a single daily dose 2 hours before bedtime)
Study: 8751230
Drug: Treatment I
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment I (B 5 ml, OT 500 mg, M 200 mg, q.i.d. for 14 days)
Study: 8751230
Drug: Treatment II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment II (B 10 ml, OT 750 mg, M 400 mg, q.i.d. for 7 days)
Study: 8751230
Drug: Treatment III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment III (B 10 ml, OT 500 mg, M 400 mg, q.i.d. for 10 days)
Study: 6951254
Drug: Chlorhexidine (1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine (1.1 mM solution)
Study: 6951254
Drug: Copper (1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper (1.1 mM solution)
Study: 6951254
Drug: Silver nitrate
Normalized name: Silver Nitrate
DrugBank: Silver (DB12965)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Silver nitrate (1.1 mM solution)
Study: 25668557
Drug: 60% wt/wt
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60% wt/wt ethanol solution
Study: 25668557
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution (control group)
Study: 23864339
Drug: Des-acyl ghrelin
Normalized name: gellan gum (low acyl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Des-acyl ghrelin (DAG) infusion (3 and 10 μg DAG/kg per h)
Study: 23864339
Drug: Des-acyl ghrelin
Normalized name: gellan gum (low acyl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Des-acyl ghrelin (DAG) infusion
Study: 23864339
Drug: Des-acyl ghrelin
Normalized name: gellan gum (low acyl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Des-acyl ghrelin (DAG) infusion during hyperinsulinemic-euglycemic clamp (HEC)
Study: 19774810
Drug: High-energy extracorporeal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy extracorporeal shock wave therapy (ESWT) - 6000 impulses (ED+ 0.78 mJ/mm2) in 3 sessions under local anaesthesia
Study: 19774810
Drug: Low-energy extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy extracorporeal shock wave therapy (ESWT) - 6000 impulses (ED+ 0.33 mJ/mm2) under local anaesthesia
Study: 17315050
Drug: Anti-inflammatory-dose doxycycline
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory-dose doxycycline (Oracea) - 40 mg capsule containing 30 mg immediate-release and 10 mg delayed-release doxycycline beads, taken once daily.
Study: 15235901
Drug: G-CSF (filgrastim,
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (filgrastim, 5 microg/kg day)
Study: 15235901
Drug: G-CSF plus
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF plus oral antibiotics (amoxicillin/clavulanate plus ciprofloxacin)
Study: 2588760
Drug: ISDN 120
Normalized name: ISDN 120 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN 120 mg ret.
Study: 2588760
Drug: ISDN 120
Normalized name: ISDN 120 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN 120 mg plus Diltiazem 120 mg ret.
Study: 31130288
Drug: Anastrozole, 1
Normalized name: Anastrozole, 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole, 1 mg/day
Study: 25575764
Drug: SOL (S-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOL (S-1 40-60 mg bid + oral LV 25 mg bid for 1 week + oxaliplatin 85 mg/m² on day 1, every 2 weeks)
Study: 24565088
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch (HES) 130/0.4, preload of 15 mL.kg(‐1)
Study: 24565088
Drug: Lactated Ringer
Normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer solution, preload of 30 mL.kg(‐1)
Study: 7774317
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (behavioral medicine counseling)
Study: 7774317
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment control group
Study: 30983609
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of topical hydroquinone 4% and fractional CO2 laser
Study: 30983609
Drug: Topical hydroquinone
Normalized name: hydroquinone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hydroquinone 4%
Study: 25300285
Drug: Cardi04 yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardi04 yogurt (300 ml milk fermented with L. helveticus)
Study: 25300285
Drug: Placebo yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo yogurt (300 ml artificially acidified milk)
Study: 16540839
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 6 mg x kg(‐1) body mass
Study: 9170475
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous study drug)
Study: 3532353
Drug: Various new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various new and commercially available drugs, surgery, and/or radiation therapy
Study: 9192927
Drug: Action Plan
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Action Plan and booklet on self-management plus supply of prednisone and antibiotics from GP
Study: 1555312
Drug: Intranasal splints
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal splints inserted for 7 days
Study: 2861791
Drug: Intranasal luteinising
Normalized name: Luteinising hormone
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal luteinising hormone releasing hormone (1200 micrograms/day for 28 days)
Study: 26807502
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg omega 3-PUFA supplementation
Study: 17687719
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluticasone propionate and salmeterol, 500/100 microg daily (group 1; n = 52)
Study: 17687719
Drug: Beclomethasone, 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone, 1000 microg daily, and salbutamol inhaler, 800 microg daily (group 2; n = 53)
Study: 15633616
Drug: Amiodarone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (200 to 400 mg/d)
Study: 9732379
Drug: Pentazocine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (7.5 to 30 mg)
Study: 28592234
Drug: Generic warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic warfarin (Uniao Quimica Farmaceutica Nacional)
Study: 28592234
Drug: Generic warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic warfarin (Laboratorio Teuto Brasileiro)
Study: 25740387
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not explicitly defined, but implied as no treatment or standard care)
Study: 23497452
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg plus Anastrozole 1 mg/day for 14 to 21 days (F + A)
Study: 23497452
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg plus Anastrozole placebo (F)
Study: 23497452
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (F, F + A, A)
Study: 16785262
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor (letrozole 2.5 mg daily from cycle days 2 to 8)
Study: 16785262
Drug: Androgen priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen priming with aromatase inhibitor and hCG (1250 IU s.c. on cycle day 2)
Study: 15385877
Drug: AGF platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGF platelet gel
Study: 15332782
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation with antirabies vaccine
Study: 15332782
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving only the antirabies vaccine
Study: 9241094
Drug: Aldactone tablets
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aldactone tablets (ALD)
Study: 8302149
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam 0.05 mg/kg, meperidine 1 mg/kg, and buscopan 20 mg (Group IV‐MMB)
Study: 8302149
Drug: Intramuscular meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine 50 mg and buscopan 20 mg (Group IM‐MB)
Study: 3127114
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of combination oral contraceptive tablet (250 micrograms LNG and 50 micrograms EE2)
Study: 3127114
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of combination oral contraceptive tablet (250 micrograms LNG and 50 micrograms EE2)
Study: 3127114
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of combination oral contraceptive tablet (250 micrograms LNG and 50 micrograms EE2)
Study: 31665873
Drug: Caffeine (CAF:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (CAF: 6 mg/kg body mass)
Study: 29157276
Drug: Non-Surgical Periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Surgical Periodontal Therapy (NSPT)
Study: 23219296
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg and simvastatin 20 to 40 mg
Study: 23219296
Drug: Lower-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose statin therapy (Atorvastatin 10 mg and simvastatin 20 to 40 mg)
Study: 14690100
Drug: Sub-Tenon's bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-Tenon's bupivacaine (4-5 mL of bupivacaine 0.75%)
Study: 8603458
Drug: No-support group
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-support group (MVP therapy without rhG‐CSF)
Study: 16967580
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (5 mg/kg body weight over 30 min)
Study: 27686945
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy plus concurrent chemoradiotherapy (3 cycles of intravenous docetaxel 60 mg/m2 on day 1, intravenous cisplatin 60 mg/m2 on day 1, continuous intravenous fluorouracil 600 mg/m2 per day from day 1 to day 5 every 3 weeks)
Study: 27686945
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy alone (3 cycles of 100 mg/m2 cisplatin every 3 weeks with intensity-modulated radiotherapy)
Study: 20205486
Drug: Tolvaptan 15-60
Normalized name: tolvaptan 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 15-60 mg once daily for up to 30 days (n = 95 in SALT-1, n = 118 in SALT-2)
Study: 20205486
Drug: Tolvaptan in
Normalized name: Product containing tolvaptan in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan in a subgroup of 323 patients with hyponatraemia (serum sodium <134 mmol/L) in the EVEREST trials
Study: 18204388
Drug: Cervical foramenal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical foramenal or epidural injections
Study: 12114414
Drug: Pivaloyloxymethyl butyrate
Normalized name: Pivaloyloxymethyl butyrate
DrugBank: AN-9 (DB05103)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivaloyloxymethyl butyrate (AN‐9) administered as a 6‐h i.v. infusion daily for 5 days every 3 weeks at dosages ranging from 0.047 to 3.3 g/m2/day.
Study: 12114414
Drug: Pivaloyloxymethyl butyrate
Normalized name: Pivaloyloxymethyl butyrate
DrugBank: AN-9 (DB05103)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivaloyloxymethyl butyrate (AN‐9) at maximum deliverable dose of 3.3 g/m2/day.
Study: 12114414
Drug: Pivaloyloxymethyl butyrate
Normalized name: Pivaloyloxymethyl butyrate
DrugBank: AN-9 (DB05103)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivaloyloxymethyl butyrate (AN‐9) treatment.
Study: 8061266
Drug: Ketanserin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (5 mg)
Study: 31983585
Drug: Human rotavirus
Normalized name: Live attenuated human Rotavirus RIX4414 strain Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human rotavirus vaccine (HRV), Rotarix, administered over a three-year period.
Study: 22730906
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg paracetamol
Study: 22730906
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg etodolac
Study: 22730906
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg etodolac
Study: 11103193
Drug: PCEA ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA ropivacaine 0.1%, bolus 5 mg, lock-out 15 min, 3 mg h-1 background infusion (group R)
Study: 11103193
Drug: PCEA 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA 0.1% ropivacaine/fentanyl 2 micrograms ml-1 at identical settings (group RF)
Study: 30939410
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 800 mg qAM
Study: 30939410
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 400 mg BID
Study: 20510947
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (listening to music during the procedure)
Study: 20510947
Drug: No music
Approvals — FDA: no, EMA: no, PMDA: no
Description: No music therapy (control group)
Study: 12030956
Drug: Intravenous H2-receptor
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous H2-receptor antagonists
Study: 2188335
Drug: AGD (aluminium‐adsorbed
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGD (aluminium‐adsorbed allergoid) injections
Study: 2188335
Drug: TA (tyrosine‐adsorbed
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA (tyrosine‐adsorbed allergoid) injections
Study: 6268298
Drug: Cefotaxime 500
Normalized name: cefotaxime 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 500 mg intramuscularly every eight hours
Study: 6268298
Drug: Cefazolin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1,000 mg intramuscularly every eight hours
Study: 22638798
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg every 2 weeks), Everolimus (5 mg three times weekly), Panitumumab (4.8 mg/kg)
Study: 22638798
Drug: Everolimus (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (5 mg daily)
Study: 14604447
Drug: Fluvoxamine CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine CR (100-300 mg/d)
Study: 9571327
Drug: Simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10 mg once nightly for 8 weeks, 20 mg for the next 8 weeks, and 40 mg for the third 8-week period)
Study: 9571327
Drug: Gemfibrozil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (600 mg twice daily throughout the 24 weeks)
Study: 7849231
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg R(‐)‐ibuprofen
Study: 7849231
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg S(+)‐ibuprofen
Study: 7849231
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg R(‐)(‐)+300 mg S(+)‐ibuprofen
Study: 7849231
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg R(‐)(‐)+600 mg S(+)‐ibuprofen
Study: 2468859
Drug: Nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10 mg b.i.d.)
Study: 7679615
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg b.i.d.)
Study: 2468859
Drug: Nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10 mg q.d.) + Captopril (25 mg b.i.d.)
Study: 27558768
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1.0‐1.5 g/day for 6 months, then 0.5‐0.75 g/day for another 6 months
Study: 23538168
Drug: Prulifloxacin 600
Normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600 mg once a day for 7 days
Study: 23538168
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg once a day for 7 days
Study: 21329626
Drug: Extended-release (ER)
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release (ER) dexibuprofen (450 mg, b.i.d.)
Study: 21329626
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) dexibuprofen (300 mg, t.i.d.)
Study: 10335001
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Budesonide and Terbutaline)
Study: 9652764
Drug: FAC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC regimen (5-fluorouracil 600 mg/m² i.v. over 1 h on days 1, 2, 3; doxorubicin 50 mg/m² i.v. bolus on day 1; cyclophosphamide 400 mg/m² i.v. bolus on days 1, 2, 3)
Study: 9652764
Drug: FULON regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FULON regimen (5-fluorouracil 250 mg/m² day(-1) continuously infused from day 1 to day 22; doxorubicin 15 mg/m² i.v. bolus on days 1, 8, 15, 22; cyclophosphamide 300 mg/m² i.v. bolus on days 1, 8, 15, 22)
Study: 336135
Drug: Carbohydrate restriction
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate restriction with phenformin (50 mg/day)
Study: 336135
Drug: Hypolipidaemic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypolipidaemic treatment (supplemented when necessary)
Study: 29294732
Drug: Individual Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Cognitive-Behavioral Therapy (ICBT) for 20 sessions
Study: 29294732
Drug: Group Cognitive-Behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive-Behavioral Therapy (GCBT) for 20 weeks
Study: 20694508
Drug: Individual Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Cognitive-Behavioral Therapy (ICBT)